BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Decnupaz (Pivekimab Sunirine) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Decnupaz (Pivekimab Sunirine)\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04086264-2846@assetmemo.bio
DTSTAMP:20261121T010141Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Decnupaz (Pivekimab Sunirine): Phase 1/2 readout est. (NCT04086264)
DESCRIPTION:Decnupaz (Pivekimab Sunirine)\, phase 1/2\, Acute Myeloid Leuke
 mia.\nStudy: IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine 
 for Participants With CD123-Positive Acute Myeloid Leukemia\nEstimated pri
 mary completion: February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pivekimab-sunirine#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04086264
URL:https://assetmemo.bio/drug/pivekimab-sunirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07306832-2846@assetmemo.bio
DTSTAMP:20261121T010141Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Decnupaz (Pivekimab Sunirine): Phase 1 readout est. (NCT07306832)
DESCRIPTION:Decnupaz (Pivekimab Sunirine)\, phase 1\, Acute Myeloid Leukemi
 a.\nStudy: A Study to Assess Adverse Events and How Intravenous (IV) Pivek
 imab Sunirine Moves Through the Body in Pediatric Participants With Relaps
 ed or Refractory Acute Myeloid Leukemia (AML)\nEstimated primary completio
 n: April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/piveki
 mab-sunirine#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07306832
URL:https://assetmemo.bio/drug/pivekimab-sunirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581002-2846@assetmemo.bio
DTSTAMP:20261121T010141Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Decnupaz (Pivekimab Sunirine): Phase 2/3 readout est. (NCT07581002)
DESCRIPTION:Decnupaz (Pivekimab Sunirine)\, phase 2/3\, Acute Myeloid Leuke
 mia.\nStudy: A Study to Assess Adverse Events and Change in Disease Activi
 ty When Intravenous (IV) Pivekimab Sunirine is Given in Combination With O
 ral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants Wi
 th Acute Myeloid Leukemia (AML)\nEstimated primary completion: June 2032. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/pivekimab-sunirine#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075810
 02
URL:https://assetmemo.bio/drug/pivekimab-sunirine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
